News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

OLE reflects long-term efficacy, safety of mirikizumab for CD
18 Feb 2025
byAudrey Abella
Initial findings from the ongoing VIVID-2 open-label extension (OLE) study comprising week 52 endoscopic responders from the phase III VIVID-1 trial demonstrate the long-term clinical and endoscopic efficacy of the selective anti-interleukin-23p19 monoclonal antibody mirikizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
18 Feb 2025

SC dose escalation restores efficacy of infliximab in IBD patients
17 Feb 2025
byStephen Padilla
Escalating the dose of subcutaneous (SC) CT-P13, a biosimilar of infliximab, from 120 to 240 mg every 2 weeks appears to bring back the efficacy of the drug in patients with inflammatory bowel disease (IBD) who no longer respond to treatment, suggests a study presented at 2025 Crohn's & Colitis Congress.
17 Feb 2025






